{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:25:21Z","timestamp":1790378721969,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF\u20102022R1F1A1063144"],"award-info":[{"award-number":["NRF\u20102022R1F1A1063144"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Fibroblast growth factor (FGF)\u201021 analogs are potential therapeutic candidates for metabolic dysfunction\u2010associated steatohepatitis (MASH). This systematic review and meta\u2010analysis aimed to assess the efficacy and safety of the FGF\u201021 analogs, efruxifermin, pegbelfermin, and pegozafermin for MASH treatment. A comprehensive systematic review and meta\u2010analysis of randomized controlled trials from five major databases was conducted. Primary efficacy outcomes focused on liver histological improvement, while secondary efficacy outcomes encompassed reductions in liver fat content and improvements in biochemical parameters. Safety outcomes examined included treatment\u2010emergent adverse events (TEAEs), treatment\u2010related TEAEs, TEAEs leading to discontinuation, and serious TEAEs. Eight eligible studies involving 963 patients were included in this review. Compared with the placebo group, the FGF\u201021 analog\u2010treated group exhibited significantly improved primary efficacy outcomes, specifically \u22651 stage improvement in fibrosis with no worsening of MASH (risk ratio [RR]\u2009=\u20091.83; 95% confidence interval [CI]\u2009=\u20091.27\u20132.62) and at least two\u2010point improvement in the non\u2010alcoholic fatty liver disease activity score with no worsening of fibrosis (RR\u2009=\u20092.85; 95% CI\u2009=\u20092.06\u20133.95). Despite an increased risk of TEAEs (RR\u2009=\u20091.17; 95% CI\u2009=\u20091.08\u20131.27) and treatment\u2010related adverse events (RR\u2009=\u20091.75; 95% CI\u2009=\u20091.40\u20132.19), FGF\u201021 analogs exhibited an acceptable safety profile. FGF\u201021 analogs were significantly better in achieving liver histological improvements and beneficial biochemical outcomes compared with placebo, with a tolerable safety pattern. These findings shed light on the efficacy and safety of FGF\u201021 analogs and provide valuable evidence for their application as MASH therapeutics.<\/jats:p>","DOI":"10.1002\/cpt.3278","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T11:29:01Z","timestamp":1714130941000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and Safety of Fibroblast Growth Factor\u201021 Analogs for the Treatment of Metabolic Dysfunction\u2010Associated Steatohepatitis: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"116","author":[{"given":"Changhyeon","family":"Jeong","sequence":"first","affiliation":[{"name":"College of Pharmacy, Kyungsung University  Busan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-8564","authenticated-orcid":false,"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Jeju National University  Jeju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-8841","authenticated-orcid":false,"given":"Nakyung","family":"Jeon","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute for Drug Development Pusan National University  Busan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-0837","authenticated-orcid":false,"given":"Su\u2010jin","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy College of Pharmacy, Wonkwang University  Iksan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-9376","authenticated-orcid":false,"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[{"name":"School of Pharmacy Pharmacy Australia Centre of Excellence, The University of Queensland  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min\u2010Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute for Drug Development Pusan National University  Busan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-0565","authenticated-orcid":false,"given":"In\u2010hwan","family":"Baek","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Kyungsung University  Busan Korea"},{"name":"School of Pharmacy Pharmacy Australia Centre of Excellence, The University of Queensland  Brisbane Queensland Australia"},{"name":"Functional Food &amp; Drug Convergence Research Center, Industry\u2010Academic Cooperation Foundation Kyungsung University  Busan Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"e_1_2_12_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2008.12.015"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10568-z"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071963"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101231"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.03.041"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103910"},{"key":"e_1_2_12_11_1","first-page":"1","article-title":"The role of FGF21 and its analogs on liver associated diseases","volume":"9","author":"Falamarzi K.","year":"2022","journal-title":"Front. Med (Lausanne)."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-032322-093904"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2019.12.005"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.012"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"e_1_2_12_16_1","unstructured":"Higgins J.P.T.et al.Cochrane Handbook for Systematic Reviews of Interventionsversion 6.4 (updated August 2023). Cochrane <www.training.cochrane.org\/handbook> (2023). Accessed September 25 2023."},{"key":"e_1_2_12_17_1","unstructured":"Higgins J.P.T.et al.Methodological Expectations of Cochrane Intervention Reviews. Cochrane<https:\/\/community.cochrane.org\/mecir\u2010manual> (2022). Accessed September 25 2023."},{"key":"e_1_2_12_18_1","first-page":"E122","article-title":"Efruxifermin in nonalcoholic steatohepatitis with fibrosis: results from a randomized, double\u2010blind, placebo\u2010controlled, phase 2b trial (HARMONY). Conference proceeding","volume":"77","author":"Harrison S.A.","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01425-3"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100563"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.011"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31785-9"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00347-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.10.051"},{"key":"e_1_2_12_26_1","unstructured":"US Food and Drug Administration.Guidance for industry: Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. <https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/noncirrhotic\u2010nonalcoholic\u2010steatohepatitis\u2010liver\u2010fibrosis\u2010developing\u2010drugs\u2010treatment> (2018). Accessed September 25 2023."},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29085"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12565"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02242-6"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.20945\/2359-4292-2022-0493"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115871"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102227"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1917"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1708898"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.001"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T19:04:00Z","timestamp":1718564640000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/cpt.3278"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3278","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"assertion":[{"value":"2024-02-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}